Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DONEPEZIL HCL

All products: Limited Use (codes 347, 348)

Other products in the same Health Canada class (N06DA) — coverage varies; not interchangeable

  • Galantamine (Reminyl ER): limited Use 347, 348, Not a benefit
  • Rivastigmine (Exelon): limited Use 347, 348, Not a benefit

Aricept · DIN 02232043 · 5mg · tablet

Limited Use — Reason for Use code 347, 348 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 347, 348 required
Write on scriptLU code 347, 348 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 347, 348
Reason for Use code 347 Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed. Network note: Maximum duration 3 months. Coverage limit: LU Authorization Period: 1 year Reason for Use code 348 Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26. Coverage limit: LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Aricept (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Aricept · DIN 02232043 Manufacturer: Pfizer Canada Inc.; listing date 1999-06-01 Health Canada: Marketed since 1997-08-20 · brand ARICEPT · ATC N06DA02 DONEPEZIL · form Tablet · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4586 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51491 · Verify on the e-Formulary ↗ (DIN 02232043)

Source record
DIN 02232043: Aricept Raw flags: sec12=Y, sec3=Y Item: 120400017; group id 193; item number 0354; lccId 00026; manufacturer id PFI Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.1856; ministry $0.4586 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232043 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51491
Interchangeable products
AG-Donepezil · DIN 02432684 · $0.4586 Ach-Donepezil · DIN 02402645 · $0.4586 Apo-Donepezil · DIN 02362260 · $0.4586 Auro-Donepezil · DIN 02400561 · $0.4586 Bio-Donepezil · DIN 02412853 · $0.4586 Co Donepezil · DIN 02397595 · $0.4586 Donepezil · DIN 02420597 · $0.4586 Donepezil · DIN 02426846 · $0.4586 Donepezil · DIN 02475278 · $0.4586 Jamp-Donepezil · DIN 02404419 · $0.4586 Jamp-Donepezil Tablets · DIN 02416948 · $0.4586 M-Donepezil · DIN 02467453 · $0.4586 Mar-Donepezil · DIN 02402092 · $0.4586 Mint-Donepezil · DIN 02408600 · $0.4586 NRA-Donepezil · DIN 02535386 · $0.4586 PMS-Donepezil · DIN 02322331 · $0.4586 Ran-Donepezil · DIN 02381508 · $0.4586 Sandoz Donepezil · DIN 02328666 · $0.4586 Septa-Donepezil · DIN 02428482 · $0.4586 Teva-Donepezil · DIN 02340607 · $0.4586
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL, PYRIDOSTIGMINE BROMIDE 12:04 Parasympathomimetic (Cholinergic) Agents

GALANTAMINE HYDROBROMIDE

· 18 products · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) · strengths: 8mg, 16mg, 24mg · ER Cap

RIVASTIGMINE

· 34 products · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.5mg, 3mg, 4.5mg, 6mg, 9mg/5 Sq Cm, 18mg/10 Sq Cm · Cap, Trans Patch

BETHANECHOL CHLORIDE

· 3 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

PYRIDOSTIGMINE BROMIDE

· 4 products · General benefit · strengths: 180mg, 60mg · LA Tab, Tab

PILOCARPINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:04
Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: dementia of the alzheimers type
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. GALANTAMINE HYDROBROMIDE · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) Indications Galantamine ER (galantamine extended release capsules) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer’s type. PM: https://pdf.hres.ca/dpd_pm/00085752.PDF; date 2026-08-11; DIN 02316943; fetched 2026-09-10 Product monograph RIVASTIGMINE · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) 1 INDICATIONS EXELON® (rivastigmine hydrogen tartrate) is indicated for: • The symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. PM: https://pdf.hres.ca/dpd_pm/00085220.PDF; date 2026-07-02; DIN 02242115; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ARICEPT (donepezil hydrochloride) is indicated for: • symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer’s type. Efficacy of ARICEPT in patients with mild to moderate Alzheimer’s disease was established in two 24 week and one 54-week placebo-controlled trials. Efficacy in patients with severe Alzheimer’s disease was established in three 24-week/6-month placebo-controlled trials. ARICEPT tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer’s disease. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Dose escalation in patients > 85 years old should proceed with caution (see 4.1 Dosing Considerations; and 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00077966.PDF PM date: AUG 12, 1997 Source product: ARICEPT; DIN 02232043; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.